If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaven I&g 4 Regulatory News (MAV4)

Share Price Information for Maven I&g 4 (MAV4)

Share Price is delayed by 15 minutes
Get Live Data
50.00    0.00 (0.00%)
Bid:
49.00
Ask:
51.00
Spread: 2.00 (4.082%)
Market Cap: £83.71m
MAV4 Live PriceLast checked at - London Stock Exchange

Intraday Maven I&g 4 Share Chart

Merger Update: Approval of Scheme

15 Nov 2018 15:01

RNS Number : 5253H
Maven Income & Growth VCT 4 PLC
15 November 2018
 

Maven Income and Growth VCT 4 PLC ("MIG4")

Maven Income and Growth VCT 2 PLC ("MIG2")

(together the "Companies")

15 November 2018

Merger Update: Approval of Scheme

This announcement is made by the Companies in connection with the scheme of reconstruction of MIG2 (the "Scheme"), details of which were contained in the prospectus issued by MIG4 on 5 October 2018 (the "Prospectus"), and the circulars (the "Circulars") and the announcements issued by the Companies on the same date.

The boards of directors of the Companies are pleased to report that the resolution proposed at the second general meeting of MIG2 held today (the "Second General Meeting") was duly passed and that the Scheme has become unconditional.

In implementing the Scheme, the assets and liabilities of MIG2 have been transferred to MIG4, in consideration for the issue of a total of 19,469,302 ordinary shares of 10p each in the capital of MIG4 ("Scheme Shares") to the former shareholders of MIG2 at a deemed issue price of 70.5621p per Scheme Share. Pursuant to the Scheme, Scheme Shares were issued to the former shareholders of MIG2 at a ratio of 0.485100 Scheme Shares for each MIG2 share held. The net asset value of MIG4 following the Scheme is £54,470,837.

Following the issue of the Scheme Shares, the total number of MIG4's issued ordinary shares of 10p each is 77,195,595.

Following the implementation of the Scheme, MIG2 has been placed in members' voluntary liquidation.

Application has been made to the London Stock Exchange for the Scheme Shares to be admitted to trading on its main market for listed securities and it is expected that the Scheme Shares will be admitted to the Official List and that trading will become effective on 16 November 2018.

MIG2 also announces that further to the resolution passed at the Second General Meeting, the listing of its ordinary shares of 10p each on the Official List of the UK Listing Authority will be cancelled with effect from 7.30 am on 16 November 2018.

As set out in the Prospectus, one of the existing directors of MIG2, Peter Linthwaite, has now been appointed as a director of MIG4. As stated in the Circular of MIG2, as the Scheme has now taken effect, John Lawrence and The Hon. Robert Kissin have now resigned as directors of MIG2.

A copy of the resolution passed at the Second General Meeting has been submitted to the National Storage Mechanism and will shortly be available for inspection at: www.morningstar.co.uk/uk/NSM.

Issued on behalf of the Board

 

Maven Capital Partners UK LLP

Secretary of each of the Companies

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCBSBDBCUBBGIU
Date   Source Headline
20th May 202610:12 amRNSAdmission of Further Securities to Trading
15th May 202610:45 amRNSDirector/PDMR Shareholding
15th May 202610:41 amRNSIssue of Equity - Dividend Investment Scheme
14th May 20265:22 pmRNSTransaction in Own Shares
12th May 20263:37 pmRNSUnaudited NAV - Dividend Investment Scheme
7th May 20261:45 pmRNSResult of AGM
30th Apr 202610:58 amRNSAdmission of Further Securities to Trading
29th Apr 202612:29 pmRNSIssue of Equity
20th Apr 202612:23 pmRNSPublication of a Supplementary Prospectus
15th Apr 202611:27 amRNSAdmission of Further Securities to Trading
14th Apr 202611:09 amRNSIssue of Equity
10th Apr 202612:02 pmRNSUnaudited Net Asset Value
8th Apr 20269:33 amRNSAdmission of Further Securities to Trading
25th Mar 20263:51 pmRNSTransaction in Own Shares
25th Mar 202610:55 amRNSAdmission of Further Securities to Trading
24th Mar 202612:11 pmRNSIssue of Equity
19th Mar 20264:21 pmRNSUnaudited NAV and Proposed Final Dividend
18th Feb 20264:58 pmRNSAdmission of Further Securities to Trading
17th Feb 202611:07 amRNSDirector/PDMR Shareholding
17th Feb 202611:07 amRNSDirector/PDMR Shareholding
17th Feb 202610:54 amRNSIssue of Equity
4th Feb 20267:00 amRNSStatement re Offer for Subscription
21st Jan 202611:07 amRNSAdmission of Further Securities to Trading
20th Jan 20262:05 pmRNSAdmission of Further Securities to Trading
16th Jan 20269:52 amRNSDirector/PDMR Shareholding
16th Jan 20269:44 amRNSIssue of Equity
15th Jan 202610:36 amRNSDirector/PDMR Shareholding
15th Jan 202610:35 amRNSDirector/PDMR Shareholding
15th Jan 20269:55 amRNSIssue of Equity
14th Jan 20262:39 pmRNSUnaudited NAV - Dividend Investment Scheme
13th Jan 202612:10 pmRNSUnaudited Net Asset Value
4th Dec 202510:35 amRNSSecond Interim Dividend
18th Nov 20253:48 pmRNSTransaction in Own Shares
14th Nov 20259:31 amRNSNet Asset Value(s)
13th Nov 20254:53 pmRNSResult of General Meeting
2nd Oct 20254:42 pmRNSPublication of a Prospectus
29th Aug 20257:00 amRNSDirector/PDMR Shareholding
29th Aug 20257:00 amRNSIssue of Equity
29th Aug 20257:00 amRNSHalf-year Report
20th Aug 20252:14 pmRNSStatement re Dividend Investment Scheme
31st Jul 20254:42 pmRNSTransaction in Own Shares
16th Jul 202510:18 amRNSStatement re Unaudited NAV and Interim Dividend
16th Jul 20257:08 amRNSStatement re Offer for Subscription
21st May 20254:44 pmRNSTransaction in Own Shares
16th May 20259:30 amRNSDirector/PDMR Shareholding
16th May 20259:26 amRNSIssue of Equity - Dividend Investment Scheme
9th May 20251:53 pmRNSStatement re Dividend Investment Scheme
9th May 202510:03 amRNSNet Asset Value(s)
8th May 20251:43 pmRNSResult of AGM
6th May 202511:55 amRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.